KR
Krystal Biotech, Inc.$KRYSStrong FundamentalsStrong FundamentalsRevenue growing 32% YoY at strong marginsStreet coverage with positive forward estimatesQuiet on X (52 mentions/wk)
BiotechnologyBullish sentiment
Krystal Biotech posts frame Q2 as a pristine cash machine: revenue $119.2M up 24% year over year, net income $54.8M, gross margins at 95% and the balance sheet crossing $1.1B. VYJUVEK global revenue $119.2M and $965.9M since launch reinforce the durable-growth story, with brief pullback pressure.
Proven numbers
Krystal Biotech commercializes VYJUVEK (B-VEC) for dystrophic epidermolysis bullosa — the first-ever FDA-approved topical gene therapy. The business is a rare profitable commercial-stage biotech.
• The economics are elite: Q1 revenue +32% YoY at a 42.8% operating margin and ROIC of 13.9% — top-decile biotech metrics, with Q2 revenue reportedly $119.2M (+24% YoY) and net income $54.8M at 95% gross margins.
• The commercial momentum is specific: VYJUVEK global revenue $119.2M in Q2 and $965.9M since launch — a durable-growth story with the balance sheet crossing $1.1B.
• 52-week range position is 72% with volume at 86% of average — upper-mid range on quiet volume, consolidating ahead of Nov 2 earnings as the next catalyst.
Nov 2 Q3 is the gate — any continued VYJUVEK uptake plus pipeline updates extend the move. A VYJUVEK growth deceleration or any pipeline setback and the stock gives back some gain.
